Swiss National Bank Grows Position in Amgen Inc. (NASDAQ:AMGN)

Swiss National Bank increased its holdings in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 0.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,592,233 shares of the medical research company's stock after buying an additional 5,500 shares during the period. Swiss National Bank owned about 0.30% of Amgen worth $513,033,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in AMGN. Capital International Investors increased its position in shares of Amgen by 547.8% during the 1st quarter. Capital International Investors now owns 7,005,269 shares of the medical research company's stock worth $1,991,738,000 after purchasing an additional 5,923,915 shares during the last quarter. Pathway Financial Advisers LLC boosted its holdings in Amgen by 33,125.4% during the 3rd quarter. Pathway Financial Advisers LLC now owns 4,460,181 shares of the medical research company's stock valued at $1,437,115,000 after acquiring an additional 4,446,757 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Amgen by 6,812.4% in the 3rd quarter. International Assets Investment Management LLC now owns 2,523,387 shares of the medical research company's stock valued at $8,130,610,000 after buying an additional 2,486,882 shares during the period. Janus Henderson Group PLC boosted its stake in shares of Amgen by 137.1% in the 1st quarter. Janus Henderson Group PLC now owns 2,381,133 shares of the medical research company's stock valued at $676,984,000 after buying an additional 1,377,007 shares during the period. Finally, Assenagon Asset Management S.A. boosted its stake in shares of Amgen by 561.5% in the 3rd quarter. Assenagon Asset Management S.A. now owns 1,539,733 shares of the medical research company's stock valued at $496,117,000 after buying an additional 1,306,982 shares during the period. Hedge funds and other institutional investors own 76.50% of the company's stock.

Amgen Stock Down 4.2 %

AMGN opened at $283.61 on Friday. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a market cap of $152.45 billion, a P/E ratio of 36.31, a PEG ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 52 week low of $260.52 and a 52 week high of $346.85. The business's fifty day simple moving average is $320.85 and its 200 day simple moving average is $318.36.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its quarterly earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.11 by $0.47. Amgen had a return on equity of 168.35% and a net margin of 13.00%. The firm had revenue of $8.50 billion for the quarter, compared to analyst estimates of $8.50 billion. During the same period last year, the company earned $4.96 EPS. The firm's quarterly revenue was up 23.2% on a year-over-year basis. As a group, equities research analysts anticipate that Amgen Inc. will post 19.51 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Shareholders of record on Monday, November 18th will be paid a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date is Monday, November 18th. Amgen's payout ratio is 115.24%.

Analysts Set New Price Targets

Several research firms recently weighed in on AMGN. Wells Fargo & Company cut Amgen from an "overweight" rating to an "equal weight" rating and boosted their target price for the stock from $320.00 to $335.00 in a research note on Wednesday, August 7th. Wolfe Research initiated coverage on Amgen in a report on Friday. They issued a "peer perform" rating on the stock. Royal Bank of Canada reissued an "outperform" rating and issued a $362.00 target price on shares of Amgen in a report on Thursday, September 26th. Truist Financial lowered Amgen from a "buy" rating to a "hold" rating and upped their price objective for the stock from $320.00 to $333.00 in a report on Monday, October 14th. Finally, Dbs Bank raised Amgen to a "strong-buy" rating in a report on Monday, September 16th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $333.57.

About Amgen

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.